跳至主要内容
临床试验/NCT02916173
NCT02916173已完成3 期

Triggering of Follicular Maturation Using Human Chorionic Gonadotrophin With Gonadotrophin Releasing Hormone Agonist Versus Human Chorionic Gonadotrophin Alone in Antagonist Protocol in Assisted Reproductive Technology : a Randomized Controlled Trial

Assiut University1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2016年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
160
试验地点
1
主要终点
Number of M II oocytes in both groups

研究概览

简要总结

The follicular phase of the menstrual cycle involves the hourly release of gonadotropin-releasing hormone, which binds to receptors on the gonadotropes. This results in the secretion of follicle stimulating hormone and luteinizing hormone in hourly pulses that regulate follicular growth. At midcycle, rapidly rising estradiol from the dominant follicle and a small rise in progesterone lead to a gonadotrophic surge. An increase in the amplitude of Luteinizing hormone and Follicle stimulating hormone pulses initiates oocyte maturity and triggers ovulation approximately

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Infertile couples wishing to do intracytoplasmic injection trial .
  • first intracytoplasmic injection trial
  • Body mass index:18-
  • 5-Antral follicular count: more than 5 follicles in one ovary 6-normal, mild or moderate male factor infertility. 7- Antimullerian hormone >1 ng/ml

排除标准

  • Azoospermic male.
  • Body mass index more than
  • Patients with endometriosis .
  • Antimullerian hormone < 1 ng/ml

研究组 & 干预措施

Human chorionic gonadotrophin group

Experimental

Patients will receive Human chorionic gonadotrohpin injection 5000 unit

干预措施: Recombinant Human Chorionic Gonadotrophin (Drug)

Human chorionic gonadotrophin + agonist group

Active Comparator

patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate

干预措施: human chorionic gonadotrophin + gonadotrophin releasing hormone agonist (Drug)

结局指标

主要结局

Number of M II oocytes in both groups

时间窗: 24 hours

次要结局

  • Fertilization rate in each group(3 days)
  • Clinical pregnancy rate in each group(15 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ahmed Mohamed Abbas

dr

Assiut University

研究点 (1)

Loading locations...

相似试验